Detalhe da pesquisa
1.
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma.
Blood
; 2024 May 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38728378
2.
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1.
Blood
; 2024 Apr 24.
Artigo
Inglês
| MEDLINE | ID: mdl-38657201
3.
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.
Blood
; 2024 May 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38728430
4.
Teclistamab in Relapsed or Refractory Multiple Myeloma.
N Engl J Med
; 387(6): 495-505, 2022 08 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35661166
5.
GPRC5D-Targeted CAR T Cells for Myeloma.
N Engl J Med
; 387(13): 1196-1206, 2022 09 29.
Artigo
Inglês
| MEDLINE | ID: mdl-36170501
6.
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.
Blood
; 141(7): 756-765, 2023 02 16.
Artigo
Inglês
| MEDLINE | ID: mdl-36327160
7.
Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.
Blood
; 141(19): 2359-2371, 2023 05 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36626250
8.
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.
Lancet Oncol
; 2024 May 28.
Artigo
Inglês
| MEDLINE | ID: mdl-38821074
9.
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Lancet Oncol
; 25(5): e205-e216, 2024 05.
Artigo
Inglês
| MEDLINE | ID: mdl-38697166
10.
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
Br J Haematol
; 204(6): 2227-2232, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38504552
11.
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
Blood
; 139(4): 492-501, 2022 01 27.
Artigo
Inglês
| MEDLINE | ID: mdl-34269818
12.
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Blood
; 139(6): 835-844, 2022 02 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34289038
13.
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
Am J Hematol
; 99(7): 1257-1268, 2024 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-38622840
14.
Bone marrow Ki-67 index is of prognostic value in newly diagnosed multiple myeloma.
Eur J Haematol
; 111(3): 373-381, 2023 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-37311695
15.
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach.
Am J Hematol
; 98(3): 421-431, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36588413
16.
Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.
Future Oncol
; 19(34): 2297-2311, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37497629
17.
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma.
Future Oncol
; 19(1): 7-17, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-36779512
18.
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.
Future Oncol
; 19(12): 811-818, 2023 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-37132225
19.
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma.
Future Oncol
; 19(13): 887-895, 2023 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-37212642
20.
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
Lancet Oncol
; 23(1): 65-76, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34871550